1 day Ago By ABMN Staff
Investment analysts at Leerink Partners started coverage on shares of Oruka Therapeutics ( NASDAQ:ORKA – Get Free Report ) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $44.00 price target on the stock.
Leerink Partners’ price target suggests a potential upside of 73.36% from the stock’s previous close. Several other equities research analysts also recently issued reports on the company.
TD Cowen started coverage on Oruka Therapeutics in a report on Monday. They set a “buy” rating for the company. Jefferies Financial Group started coverage on Oruka Therapeutics in a report on Friday, September 13th.
They set a “buy” rating and a $40.00 price target for the company. Wedbush initiated coverage on Oruka Therapeutics in a report on Wednesday, September 4th.
They set an “outperform” rating and a $40.00 price target for the company. Finally, Lifesci Capital initiated coverage on Oruka Therapeutics in a research report on Monday.
They set an “outperform” rating and a $41.00 price objective on the stock. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company.
According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $41.25.
Read Our Latest Analysis on Oruka Therapeutics Oruka Therapeutics Price Performance Oruka Therapeutics Company Profile ( Get Free Report ) ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.
Read More Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
